Skip to main content
SpringerLink
Log in

Diagnostik und Therapie der Neuromyelitis optica

Konsensusempfehlungen der Neuromyelitis optica Studiengruppe

Diagnosis and treatment of neuromyelitis optica

Consensus recommendations of the Neuromyelitis Optica Study Group

  • Aktuelles aus Diagnostik und Therapie
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Keine oder weniger als 4 Marklagerläsionen bzw. weniger als 3 Marklagerläsionen, wenn hiervon eine periventrikulär liegt.

  2. Wurde zu Erkrankungsbeginn kein kraniales MRT angefertigt oder ist der Befund unbekannt, sollte das früheste verfügbare MRT herangezogen werden [85].

  3. Der Nachweis von NMO-IgG mittels Immunhistochemie [43] kann durch den Nachweis von AQP4-Ak mittels rekombinanter Verfahren ersetzt werden. Voraussetzung ist, dass das gewählte rekombinante Testverfahren anhand eines NMO-IgG-positiven Kollektivs erfolgreich validiert wurde. Unter den bislang (Stand: Oktober 2010) in der wissenschaftlichen Literatur beschriebenen und gegenwärtig für diagnostische Zwecke zur Verfügung stehenden Testsystemen erfüllen lediglich die sog. zellbasierten Assays diese Voraussetzung [29, 35, 79].

Literatur

  1. Aktas O, Hartung HP (2009) Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. J Neurol 256:1906–1908

    Article  PubMed  Google Scholar 

  2. Bakker J, Metz L (2004) Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265–267

    PubMed  Google Scholar 

  3. Balcer LJ (2006) Clinical practice. Optic neuritis. N Engl J Med 354:1273–1280

    Article  PubMed  CAS  Google Scholar 

  4. Barbieri F, Buscaino GA (1989) Neuromyelitis optica in the elderly. Acta Neurol 11:247–251

    CAS  Google Scholar 

  5. Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069

    Article  PubMed  Google Scholar 

  6. Bergamaschi R (2003) Glatiramer acetate treatment in Devic’s neuromyelitis optica. Brain 126:1E-a

    Article  PubMed  Google Scholar 

  7. Bergamaschi R, Jarius S, Robotti M et al (2009) Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 256:2097–2099

    Article  PubMed  CAS  Google Scholar 

  8. Bergamaschi R, Tonietti S, Franciotta D et al (2004) Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 10:2–4

    Article  PubMed  CAS  Google Scholar 

  9. Bergamaschi R, Uggetti C, Tonietti S et al (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250:359–361

    Article  PubMed  Google Scholar 

  10. Bizzoco E, Lolli F, Repice AM et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256:1891–1898

    Article  PubMed  Google Scholar 

  11. Bonnet F, Mercie P, Morlat P et al (1999) Devic’s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 8:244–247

    Article  PubMed  CAS  Google Scholar 

  12. Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272

    PubMed  CAS  Google Scholar 

  13. Davis R, Thiele E, Barnes P, Riviello JJ Jr (1996) Neuromyelitis optica in childhood: case report with sequential MRI findings. J Child Neurol 11:164–167

    Article  PubMed  CAS  Google Scholar 

  14. Seze J de, Stojkovic T, Ferriby D et al (2002) Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 197:57–61

    Article  PubMed  Google Scholar 

  15. Filippi M, Rocca MA (2004) MR imaging of Devic’s neuromyelitis optica. Neurol Sci 25(Suppl 4):371–373

    Article  Google Scholar 

  16. Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14:12–13

    Article  Google Scholar 

  17. Ghezzi A, Bergamaschi R, Martinelli V et al (2004) Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol 251:47–52

    Article  PubMed  Google Scholar 

  18. Gold R, Hartung HP, Hohlfeld R et al (2009) Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. Ergebnisse und Empfehlungen einer Arbeitstagung des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft. Akt Neurol 36:334–344

    Article  Google Scholar 

  19. Hayakawa S, Mori M, Okuta A et al (2008) Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 196:181–187

    Article  PubMed  CAS  Google Scholar 

  20. Herrmann W, Obeid R (2008) Ursachen und frühzeitige Diagnostik von Vitamin-B12-Mangel. Dtsch Arztebl 105:680–685

    Google Scholar 

  21. Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128–1133

    Article  PubMed  Google Scholar 

  22. Jacob A, Weinshenker BG (2008) An approach to the diagnosis of acute transverse myelitis. Semin Neurol 28:105–120

    Article  PubMed  Google Scholar 

  23. Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443–1448

    Article  PubMed  Google Scholar 

  24. Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072–3080

    Article  PubMed  CAS  Google Scholar 

  25. Jarius S, Franciotta D, Bergamaschi R et al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79:1134–1136

    Article  PubMed  CAS  Google Scholar 

  26. Jarius S, Franciotta D, Bergamaschi R et al (2010) Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 48:659–663

    Article  PubMed  CAS  Google Scholar 

  27. Jarius S, Franciotta D, Bergamaschi R et al (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076–1077

    Article  PubMed  CAS  Google Scholar 

  28. Jarius S, Franciotta D, Paul F et al (2010) Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 7:52

    Article  PubMed  Google Scholar 

  29. Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298:158–162

    Article  PubMed  CAS  Google Scholar 

  30. Jarius S, Jacob S, Waters P et al (2008) Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatry 79:1084

    Article  PubMed  CAS  Google Scholar 

  31. Jarius S, Paul F, Franciotta D et al (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214

    PubMed  CAS  Google Scholar 

  32. Jarius S, Probst C, Borowski K et al (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56

    Article  PubMed  CAS  Google Scholar 

  33. Jarius S, Wildemann B (2007) Neuromyelitis optica. Nervenarzt 78:1365–1377

    Article  PubMed  CAS  Google Scholar 

  34. Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392

    Article  PubMed  CAS  Google Scholar 

  35. Kalluri SR, Illes Z, Srivastava R et al (2010) Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 67:1201–1208

    Article  PubMed  Google Scholar 

  36. Kay CS, Scola RH, Lorenzoni PJ et al (2008) NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 275:148–150

    Article  PubMed  Google Scholar 

  37. Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284

    Article  PubMed  CAS  Google Scholar 

  38. Kim W, Min SP, Sang HL et al (2010) Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 16:1229–1236

    Article  PubMed  Google Scholar 

  39. Klawiter EC, Alvarez E III, Xu J et al (2009) NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 72:1101–1103

    Article  PubMed  CAS  Google Scholar 

  40. Krampla W, Aboul-Enein F, Jecel J et al (2009) Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 19:2535–2543

    Article  PubMed  Google Scholar 

  41. Lee DH, Metz I, Berthele A et al (2010) Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol (Epub ahead of print)

  42. Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477

    Article  PubMed  CAS  Google Scholar 

  43. Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112

    Article  PubMed  CAS  Google Scholar 

  44. Lim BC, Hwang H, Kim KJ et al (2010) Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler (Epub ahead of print)

  45. Llufriu S, Castillo J, Blanco Y et al (2009) Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 73:949–953

    Article  PubMed  CAS  Google Scholar 

  46. Lotze TE, Northrop JL, Hutton GJ et al (2008) Spectrum of pediatric neuromyelitis optica. Pediatrics 122:1039–1047

    Article  Google Scholar 

  47. Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461

    Article  PubMed  Google Scholar 

  48. Mader S, Lutterotti A, Di Pauli F et al (2010) Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 5:e10455

    Article  PubMed  Google Scholar 

  49. Mandler RN, Ahmed W, Dencoff JE (1998) Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219–1220

    PubMed  CAS  Google Scholar 

  50. Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34:162–168

    Article  PubMed  CAS  Google Scholar 

  51. Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:2197–2200

    Article  PubMed  CAS  Google Scholar 

  52. McKeon A, Lennon VA, Jacob A et al (2009) Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39:87–90

    Article  PubMed  Google Scholar 

  53. Minagar A, Sheremara W (2000) Treatment of Devic’s disease with methotrexate and prednisone. Int J MS Care 2:39–43

    Google Scholar 

  54. Miyamoto K, Kusunoki S (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13:505–508

    Article  PubMed  Google Scholar 

  55. Mok CC, To CH, Mak A, Poon WL (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35:172–174

    PubMed  Google Scholar 

  56. Nakamura M, Misu T, Fujihara K et al (2009) Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15:695–700

    Article  PubMed  CAS  Google Scholar 

  57. O’Riordan JI, Gallagher HL, Thompson AJ et al (1996) Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60:382–387

    Article  Google Scholar 

  58. Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671–1672

    Article  PubMed  Google Scholar 

  59. Papeix C, Vidal JS, Seze J de et al (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256–259

    Article  PubMed  CAS  Google Scholar 

  60. Paty DW, Oger JJ, Kastrukoff LF et al (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180–185

    PubMed  CAS  Google Scholar 

  61. Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133

    Article  PubMed  Google Scholar 

  62. Paul F, Jarius S, Glumm R et al (2008) Recent findings in pathogenesis, diagnostics and therapy of neuromyelitis optica. Dtsch Med Wochenschr 133:1125–1129

    Article  PubMed  CAS  Google Scholar 

  63. Petzold A, Pittock S, Lennon V et al (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 81:109–111

    Article  PubMed  CAS  Google Scholar 

  64. Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65:629–632

    Article  PubMed  Google Scholar 

  65. Pittock SJ, Lennon VA, Seze J de et al (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78–83

    Article  PubMed  Google Scholar 

  66. Pittock SJ, Lennon VA, Krecke K et al (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63:390–396

    Article  PubMed  Google Scholar 

  67. Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964–968

    Article  PubMed  Google Scholar 

  68. Riphagen J, Modderman P, Verrips A (2010) Hiccups, nausea, and vomiting: water channels under attack! Lancet 375:954

    Article  PubMed  Google Scholar 

  69. Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019–1032

    Article  PubMed  CAS  Google Scholar 

  70. Shibasaki H, McDonald WI, Kuroiwa Y (1981) Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 49:253–271

    Article  PubMed  CAS  Google Scholar 

  71. Shimizu J, Hatanaka Y, Hasegawa M et al (2010) IFN(beta)-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75:1423–1427

    Article  PubMed  CAS  Google Scholar 

  72. Shimizu Y, Yokoyama K, Misu T et al (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255:305–307

    Article  PubMed  Google Scholar 

  73. Takahashi T, Fujihara K, Nakashima I et al (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210:307–313

    Article  PubMed  CAS  Google Scholar 

  74. Takahashi T, Miyazawa I, Misu T et al (2008) Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 79:1075–1078

    Article  PubMed  CAS  Google Scholar 

  75. Tanaka M, Tanaka K, Komori M (2009) Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62:167–170

    Article  PubMed  CAS  Google Scholar 

  76. Wandinger KP, Stangel M, Witte T et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric SLE and primary Sjögren’s syndrome. Arthritis Rheum 62:1198–1200

    Article  PubMed  CAS  Google Scholar 

  77. Watanabe S, Misu T, Miyazawa I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13:968–974

    Article  PubMed  CAS  Google Scholar 

  78. Watanabe S, Nakashima I, Misu T et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128–132

    Article  PubMed  CAS  Google Scholar 

  79. Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65:913–919

    Article  PubMed  Google Scholar 

  80. Weinshenker BG, O’Brien PC, Petterson TM et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886

    Article  PubMed  CAS  Google Scholar 

  81. Weinshenker BG, Wingerchuk DM, Vukusic S et al (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569

    Article  PubMed  CAS  Google Scholar 

  82. Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957–963

    Article  PubMed  Google Scholar 

  83. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114

    PubMed  CAS  Google Scholar 

  84. Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815

    Article  PubMed  CAS  Google Scholar 

  85. Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489

    Article  PubMed  CAS  Google Scholar 

  86. Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10:55–66

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin weist auf folgende Beziehungen hin:

C. Trebst hat Honorare für wissenschaftliche Vorträge und Reiseunterstützung erhalten von Bayer Health Care, Biogen Idec, Diamed Medizintechnik, Merck Serono, Sanofi Aventis und Talecris Biotherapeutics.

A. Berthele, S. Schippling, B. Wildemann und C. Wilke haben keine Interessenskonflikte.

S. Jarius erhält Forschungsunterstützung von Bayer Schering und Merck Serono und hat ein Fellowship des European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) erhalten.

T. Kümpfel hat Honorare für wissenschaftliche Vorträge und Reiseunterstützung erhalten von Bayer Schering, Teva/Sanofi- Aventis, Merck-Serono and Biogen-Idec sowie Forschungsunterstützung von Bayer Schering.

Author information

Authors and Affiliations

  1. Neurologische Klinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    C. Trebst

  2. Technische Universität München, München, Deutschland

    A. Berthele

  3. Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    S. Jarius & B. Wildemann

  4. Ludwig-Maximilians-Universität, München, Deutschland

    T. Kümpfel

  5. Universitätsklinikum Hamburg Eppendorf, Hamburg, Deutschland

    S. Schippling

  6. HELIOS Vorgtland-Klinikum, Plauen, Deutschland

    C. Wilke

Authors
  1. C. Trebst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Berthele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Jarius
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Kümpfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Schippling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Wildemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Neuromyelitis optica Studiengruppe (NEMOS)

Corresponding author

Correspondence to C. Trebst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trebst, C., Berthele, A., Jarius, S. et al. Diagnostik und Therapie der Neuromyelitis optica. Nervenarzt 82, 768–777 (2011). https://doi.org/10.1007/s00115-010-3192-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-010-3192-4

Search

Navigation